Skip to main content

Table 6 The association of fish oil with VAF

From: Pharmaceutical prevention strategy for arteriovenous fistula and arteriovenous graft failure

Author Design N (Control) Exposure Timing Outcome (duration) VAF development
Schmitz et al [81] Placebo-controlled 24 (12) Omega-3
4 g/day
Post
Primary patency rates of AVG (1 year) Lower risk
(75.6 % vs. 14.9%, P < 0.03)
Lok et al [80] Placebo-controlled 201 (100) Omega-3
4 g/day
Post
Primary AVG failure (1000 days) Lower risk
(3.43% vs. 5.95%, HR 0.58, 95% CI 0.44–0.75, P < 0.001)
Irish et al [68] Placebo-controlled 567 (283) Omega-3
4 g/day
Pre
Primary AVF failure (12 months) Equivalent risk
(22% vs. 23%, RR 0.98, 95% CI 0.72–1.34, P = 0.90)
  1. VAF vascular access failure, VA vascular access, AVF arteriovenous fistula, AVG arteriovenous graft, RR relative risk, HR hazard ratio, CI confidential interval, Pre pre-operative period, Post post-operative period